Geron hints at a way forward for imetelstat in myelofibrosis, but the market isn't buying it.
News & Analysis: Geron
These three cancer stocks have tremendous upside potential.
These three penny stocks have enormous upside potential, but they each come with a hefty dose of risk.
Warning: Small-cap stocks are risky, but the risk might be worth taking sometimes. Like with these three companies.
GERN earnings call for the period ending December 31, 2018.
Investors are hopeful that this struggling biotech is about to get back on track.
These biopharmaceutical startups have been losing their investors' money for decades.
Can this penny biotech stock make early-bird investors rich?
This morning's move followed an upgrade by BTIG.
Johnson & Johnson's decision to hand back imetelstat's rights caused Geron's share price to crumble last year.